Anti-VEGF-R2 / CD309 / Flk-1 / KDR3 Monoklonale Antilichaam (Kloon: DC101)

This MAb is specific to Mouse VEGFR2/FLK-1/CD309 and does not cross-react with FLK-2. VEGFR2 is a type I transmembrane glycoprotein. It is a member of the CSF-1/PDGF receptor family of type III tyrosine kinase receptors. Endothelial cells, embryonic tissues, and megakaryocytes mainly express VEGFR2. It plays an important role in the regulation of angiogenesis, vasculogenesis, and vascular permeability. The ligands of VEGFR2 include VEGF-A, VEGF-C, VEGF-D, and VEGF splice isoforms. Ligation of VEGFR2 with its ligands results in the receptor dimerization and auto-phosphorylation, stimulating endothelial cell proliferation and migration.

CD309; Fetal liver kinase 1 (FLK-1) ; KDR; Kinase insert domain receptor (a type III receptor tyrosine kinase) ; KRD1; Ly73; Protein tyrosine kinase receptor FLK1; Vascular endothelial growth factor receptor 2

Kdr (Mouse)

16542

35918

Mouse

Recombinant full-length Mouse VEGFR2 protein

DC101

WB

200 μg/mL of Ab Purified from Bioreactor Concentrate by Protein A/G. Prepared in 10mM PBS with 0.05% BSA & 0.05% azide. Also available WITHOUT BSA & azide at 1.0mg/mL.

Antibody with azide - store at 2 to 8°C. Antibody without azide - store at -20 to -80°C. Antibody is stable for 24 months. Non-hazardous.

Western Blot (Non-reducing) (2-5ug/ml) ; Blocks Binding of VEGF to VEGF-R2 (Order Ab without BSA & Azide) ; Inhibits VEGF-induced Signaling (Order Ab without BSA & Azide) ; Blocks Tumor Growth in mice (Order Ab without BSA & Azide) ; Neutralizing

Rat IgG1, kappa